MD Anderson, Astellas Pharma sign option agreement for monoclonal antibody drug targeting acute myeloid leukemia

| April 3, 2015 | 0 Comments

( University of Texas M. D. Anderson Cancer Center ) The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc.

Visit site:
MD Anderson, Astellas Pharma sign option agreement for monoclonal antibody drug targeting acute myeloid leukemia

Tags: , , , , , , , , , ,

Category: Recent News

About the Author ()

Leave a Reply